17.11.2021, 11:26
Efficiency of "Sputnik V" During Vaccination in Belarus Exceeded 96%
Source: OREANDA-NEWS
OREANDA-NEWS. The effectiveness of the Russian Sputnik V coronavirus vaccine after vaccination of 1.2 million people in Belarus was 96.3%; an article analyzing the effectiveness of the drug was published on the MedRxiv portal of preprints of scientific articles in the field of medicine, according to the Russian Direct Investment Fund.
"The Russian Direct Investment Fund announces the results of a new study of the Sputnik V coronavirus vaccine in the Republic of Belarus, which has demonstrated the high safety of the drug and the effectiveness of 96.3%," the fund said.
It notes that the analysis of the effectiveness of the vaccine given in the article is based on data from more than 1.2 million people who received both components of the drug between January and September 2021 during the vaccination campaign in Belarus.
“The high efficiency of the Russian vaccine has been confirmed, including against the delta variant of the coronavirus, which has dominated in Belarus since July of this year,” the RDIF notes.
"The study also confirms the high safety profile of Sputnik V, with mild to moderate adverse events following vaccination and no vaccine-related deaths," adds the foundation.
"The Russian Direct Investment Fund announces the results of a new study of the Sputnik V coronavirus vaccine in the Republic of Belarus, which has demonstrated the high safety of the drug and the effectiveness of 96.3%," the fund said.
It notes that the analysis of the effectiveness of the vaccine given in the article is based on data from more than 1.2 million people who received both components of the drug between January and September 2021 during the vaccination campaign in Belarus.
“The high efficiency of the Russian vaccine has been confirmed, including against the delta variant of the coronavirus, which has dominated in Belarus since July of this year,” the RDIF notes.
"The study also confirms the high safety profile of Sputnik V, with mild to moderate adverse events following vaccination and no vaccine-related deaths," adds the foundation.
Комментарии